In-hospital initiation of SGLT2 inhibitors is safe and may lower early cardiovascular death, worsening heart failure, and mortality in hospitalised patients. The post ESC 2025: Starting SGLT2 Inhibitors in Hospital May Improve Heart Failure Outcomes appeared first on European Medical Journal.
